Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$596.92 USD

596.92
2,138,161

+3.13 (0.53%)

Updated Oct 11, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.

Simbec-Orion to Adopt Veeva's (VEEV) Vault Applications

by Zacks Equity Research

Veeva's (VEEV) clinical solutions will offer Simbec-Orion real-time insights into studies in phases to accelerate trial execution.

The Zacks Analyst Blog Highlights: Abbott Laboratories, Owens & Minor, Thermo Fisher Scientific, Quidel Corp and Hologic

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Laboratories, Owens & Minor, Thermo Fisher Scientific, Quidel Corp and Hologic

LabCorp's (LH) Pixel Kit Gets EUA for Over-the-Counter Use

by Zacks Equity Research

This approval is expected to increase access to LabCorp's (LH) COVID-19 testing, thereby broadening its customer base.

Cerner's (CERN) Deal to Make Clinical Trials More Accessible

by Zacks Equity Research

Cerner (CERN) inks deal with Elligo Health Research to make clinical trials more accessible, while minimizing costs.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Investors grew bullish on Nevro's (NVRO) prospects, courtesy of the stock's solid prospects.

Zacks.com featured highlights include: Lennar Corp, TeleTech Holdings, Activision Blizzard, Thermo Fisher Scientific and ParkerHannifin

by Zacks Equity Research

Zacks.com featured highlights include: Lennar Corp, TeleTech Holdings, Activision Blizzard, Thermo Fisher Scientific and ParkerHannifin

Medtronic (MDT) Carpediem to Tap Pediatric Kidney Care Market

by Zacks Equity Research

Medtronic's (MDT) Carpediem CRRT system compares favorably with the traditional three times a week therapy session.

    Bruker (BRKR) Hits New 52-Week High: What's Driving It?

    by Zacks Equity Research

    Bruker (BRKR) is optimistic about maintaining a robust product portfolio along with its continued COVID-19-led progress.

    Illumina (ILMN)-Harvard Pilgrim Partner to Expand WGS Access

    by Zacks Equity Research

    Illumina (ILMN) signs agreement to expand the availability of WGS to enable faster and cost-effective diagnosis of genetic diseases in children.

    Trina Mukherjee headshot

    4 Top-Ranked MedTech Stocks to Bet on Heading Into 2021

    by Trina Mukherjee

    Grab these four top stocks that have shown tremendous promise despite market volatility due to the pandemic and have the potential to continue their bull run in 2021.

    HealthEquity (HQY) Q3 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    HealthEquity (HQY) delivers strong growth in Service, Custodial and Interchange segments in Q3.

    3 Reasons Growth Investors Will Love Thermo Fisher (TMO)

    by Zacks Equity Research

    Thermo Fisher (TMO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

    QIAGEN (QGEN) Launches RUO Solution to Explore Immune Response

    by Zacks Equity Research

    QIAGEN's (QGEN) latest RUO solution is expected to provide better insights into the course of the COVID-19 infection and aid in vaccine development and deployment.

    LabCorp (LH) Covance Arms Shows Momentum Amid COVID-19 Woes

    by Zacks Equity Research

    In oncology too, LabCorp (LH) receives a significant award to be the partner of choice for late-stage oncology studies from a major pharmaceutical company.

    NuVasive (NUVA) Focuses on Cervical Spine Portfolio Expansion

    by Zacks Equity Research

    The ACP system within NuVasive (NUVA) C360 is targeted to reduce common postoperative complications such as dysphagia, malalignment and adjacent level ossification.

    Sweta Killa headshot

    5 Top-Ranked Stocks With Solid Dividend Growth to Bet On

    by Sweta Killa

    These dividend growth stocks have superior fundamentals, making them quality and promising investments for the long term.

    Here's Why You Should Retain Change Healthcare (CHNG) Stock

    by Zacks Equity Research

    Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.

    NextGen (NXGN) Reinforces Its Robust Solutions Portfolio

    by Zacks Equity Research

    NextGen's (NXGN) solid solutions portfolio receives further boost with the success of its Population Health tool.

    The Zacks Analyst Blog Highlights: Quest Diagnostics, Laboratory Corporation of America, Hologic, IDEXX Laboratories and Thermo Fisher Scientific

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Quest Diagnostics, Laboratory Corporation of America, Hologic, IDEXX Laboratories and Thermo Fisher Scientific

    Veeva (VEEV) Vault Applications Get Adopted by GenesisCare

    by Zacks Equity Research

    Veeva Systems' (VEEV) clinical capabilities will allow GenesisCare Clinical CRO to rationalize trial procedures and expedite execution of the same.

    CVS Health (CVS) 2021 Selling Season Strong, LTC Arm Suffers

    by Zacks Equity Research

    Since the start of the pandemic, CVS Health (CVS) is seeing more than 40% of all specialty orders being placed digitally.

    Boston Scientific's (BSX) SCS Systems Receives FDA's Nod

    by Zacks Equity Research

    Boston Scientific's (BSX) WaveWriter Alpha portfolio of SCS Systems aims to widen the therapy options available for managing chronic pain.

    Baxter's (BAX) Vital Edge Program Aids Patient Blood Management

    by Zacks Equity Research

    Baxter's (BAX) Vital Edge program enables AdventHealth Tampa to achieve cost savings.

    Here's Why You Should Retain LHC Group (LHCG) Stock Now

    by Zacks Equity Research

    LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.